On September 3, 2024, Circle Pharma, a biopharmaceutical company dedicated to discovering and developing cell permeable macrocycles as a clinical stage of a new therapy, announced the successful completion of $90 million in Series D funding, including the conversion of a convertible note.This round of financing is led by The Column Group, with new and old investors including Nextech Invest and Euclidean Capital participating.

The funds raised from the financing will be used for the clinical development of Circle Pharma's first and only similar cyclin A/B RxL inhibitor CID-078, and to support the development of the discovery project portfolio established by the company using its MXMO macrocycle platform.

David Earp, CEO and Juris Doctor of Circle Pharma, said, "We are very grateful for the continued support of such a strong investor as we advance our pioneering work on macrocyclic therapy. This financing not only allows us to advance the clinical development of CID-078 to a critical stage, but also enables us to further advance our innovative therapy product line for cancer and other serious diseases.MXMO from Circle Pharma ™ The platform aims to combine computation driven, structure based design with advanced fully synthetic macrocyclic chemistry. Through this platform, scientists can screen a large number of virtual and physicochemical libraries based on permeability to identify early popular compounds. Artificial intelligence (AI), machine learning (ML), and rigorous physical simulations are used to evaluate various potential alternative designs and quickly explore structure activity relationships to achieve hit to lead progress. Then various variants of these compounds are synthesized in the laboratory, utilizing natural and non natural chemical components (many of which are customized and proprietary components of Circle Pharma) to optimize the lead research loop.

With the latest round of financing, Circle Pharma is fully prepared to advance its mission of developing effective therapies for cancer and other serious diseases.

About Circle Pharma

Circle Pharma, headquartered in the southern part of San Francisco, is advancing the discovery and development of an intrinsic cell permeable macrocycle that can be administered through multiple routes, including oral administration. MXMO from Circle Pharma ™ The platform combines structure based rational drug design and advanced synthetic chemistry to develop a new generation of macrocyclic therapies targeting challenging targets to meet unmet clinical needs. Circle Pharma's research and development focus is on cell cycle proteins, which are the main regulators that control the progression of cells in the cell cycle and are key drivers of many cancers. For more information, please visit:

www.circlepharma.com